Ratings P3 Health Partners Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
0.6404 ^USD	+14.36%		+28.88%	-54.58%

May. 24	P3 Health Partners Inc. announced that it has received $42.2598 million in funding from Chicago Pacific Founders, Alyeska Investment Group, L.P., Leavitt Equity Partners, Armistice Capital LLC and other investors	CI
May. 22	P3 Health Partners Inc. announced that it expects to receive $42.2598 million in funding from Chicago Pacific Founders	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.09 for the 2024 fiscal year.
The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	ESG Refinitiv
P3 HEALTH PARTNERS INC.	-54.58%	66.99M	-
MODERNA, INC.	+49.41%	57.87B	B-
LONZA GROUP AG	+41.65%	40.25B	A
IQVIA HOLDINGS INC.	-6.72%	39.94B	B
CELLTRION, INC.	-5.96%	28.54B	C
ICON PUBLIC LIMITED COMPANY	+12.99%	26.4B	B-
ALNYLAM PHARMACEUTICALS, INC.	-19.82%	19.33B	B
MEDPACE HOLDINGS, INC.	+32.35%	12.4B	C+
BIO-TECHNE CORPORATION	-0.08%	12.23B	B+
UNITED THERAPEUTICS CORPORATION	+25.18%	12.2B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality